Medicamen biotech Limited has filed its quarterly compliance certificate with stock exchanges, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The pharmaceutical company submitted the mandatory documentation for the quarter ended March 31, 2026, confirming compliance with securities dematerialization procedures.

Regulatory Compliance Submission

The company submitted its certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, to both BSE Limited and National Stock Exchange of India Limited on April 15, 2026. Company Secretary Parul Choudhary signed the compliance certificate, which covers securities dematerialization and rematerialization activities during Q4FY26.

Compliance Confirmations

The company provided specific certifications regarding its securities handling procedures during the quarter. The compliance certificate confirms that all securities comprised in the dematerialization certificates have been properly listed on stock exchanges where the company's earlier issued securities were already listed.

Additionally, the company certified that all physical certificates received for dematerialization were mutilated and cancelled after due verification. The depository's name was substituted in the company's records as the registered owner within the mandatory 30-day timeline from receipt.

Registrar Confirmation

MUFG Intime India Private Limited, formerly Link Intime India Private Limited, serves as the company's registrar and share transfer agent. The registrar provided independent confirmation on April 14, 2026, validating the company's compliance with dematerialization procedures.

The registrar confirmed that securities received from depository participants during Q4FY26 were processed according to regulatory requirements, with proper verification and record-keeping procedures followed throughout the quarter.

Medicamen Biotech Limited has issued an official clarification regarding an incorrect event display appearing on the National Securities Depository Limited (NSDL) portal under the company's login credentials. The pharmaceutical company emphasized that no such event has been initiated, authorized, or undertaken by the organization.

Clarification Details

In a regulatory filing dated April 6, 2026, the company addressed the inadvertent display on the NSDL portal. The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Company's Response

Medicamen Biotech has taken immediate action to address the situation. The company has already escalated the matter with NSDL for necessary verification and rectification of the incorrect display. Management confirmed that there is no material event or information requiring disclosure from the company's end regarding this matter.

Corporate Information

The clarification was signed by Company Secretary Parul Choudhary (ACS: 44157) on behalf of Medicamen Biotech Limited. The company maintains its registered and corporate office at Chiranjiv Tower, Nehru Place, New Delhi, and operates under CIN L74899DL1993PLC056594.

Regulatory Compliance

This disclosure demonstrates the company's commitment to maintaining transparency with stakeholders and ensuring accurate information dissemination. The proactive clarification helps prevent any potential confusion among investors and market participants regarding the company's actual corporate activities and events.